Back to search results
NCT06264609

Precision Medicine Approach for Osteoporosis - Follow Up Study

Enrolling by Invitation
PHASE4Ages 45+InterventionalTreatment
Paul F Netzel
~40 participants
Updated 2026-04-01 on ClinicalTrials.gov
What's tested:AlendronateTeriparatide

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in bone loss
Measured over 12 months

Conditions

Osteoporosis

Explore related trials

OsteoporosisErgocalciferol

NCT06264609

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Kentucky

    Lexington, Kentuckyno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Paul Netzel, DNP · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Percent change in bone loss12 months

    The primary endpoint for the follow up study will be bone loss as determined by the percent change in DXA absolute values of the lumbar spine, femoral neck, total hip and radius measured at baseline, at the end of the one-year trial; and at end of the one year follow up study. DXA is chosen because of its wide availability, low radioactivity exposure, and clinical use.